Trial Profile

Feasibility study of S-1 as additional therapy after neo-adjuvant or adjuvant chemotherapy for triple negative breast cancer(SBCCSG-14).

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Jul 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gimeracil/oteracil/tegafur (Primary)
Indications Early breast cancer; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use
Acronyms SBCCSG-14

Most Recent Events

10 Jul 2019 Status changed to completed as per results published in the Investigational New Drugs
10 Jul 2019 Results assessing feasibility, efficacy, and safety of TS-1 add on therapy in Japanese patients with triple-negative breast caner published in the Investigational New Drugs
05 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com